ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in Nashville, TN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Colorectal Cancer
Cancer
Squamous Cell Carcinoma of Head and Neck
Neoplasm Metastasis
Melanoma

Non-Small-Cell Lung Cancer trials near Nashville, TN, USA:

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

3-DXd will be evaluated in participants with metastatic or unresectable NSCLC with EGFR activating mutation or squamous or non-squamous NSCL...

Active, not recruiting
Non-Small Cell Lung Cancer (NSCLC)
Drug: HER3-DXd (FL-DP)
Drug: HER3-DXd (CTM-3 Lyo-DP)

Phase 1

Daiichi Sankyo
Daiichi Sankyo

Nashville, Tennessee, United States and 36 other locations

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with o...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Docetaxel
Drug: DS-1062a

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Nashville, Tennessee, United States and 210 other locations

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

HCC is a common cancer worldwide and a leading cause of cancer-related death. Lung cancer is the most frequently ...

Enrolling
Hepatocellular Cancer
Squamous-Cell Non-Small Cell Lung Cancer
Drug: ABBV-324
Drug: Lenvatinib

Phase 1

AbbVie
AbbVie

Nashville, Tennessee, United States and 21 other locations

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Nashville, Tennessee, United States and 123 other locations

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer (RAINFOL-05)

purpose of this study is to evaluate how well Rina-S works against lung cancer.The treatment in this study is Rina-S monotherapy (b...

Enrolling
Non-small Cell Lung Cancer (NSCLC)
Drug: Rina-S

Phase 2

Genmab
Genmab

Nashville, Tennessee, United States and 40 other locations

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN)

to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non...

Active, not recruiting
Metastatic Non-Small Cell Lung Cancer (NSCLC)
Drug: AZD2936
Drug: Pemetrexed

Phase 1

AstraZeneca
AstraZeneca

Nashville, Tennessee, United States and 40 other locations

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell...

Enrolling
Non-Small Cell Lung Cancer
Drug: Telisotuzumab Vedotin

Phase 2

AbbVie
AbbVie

Nashville, Tennessee, United States and 77 other locations

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non...

Begins enrollment this month
Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Metastatic Non-Small Cell Lung Cancer (NSCLC)
Drug: Pumitamig
Drug: Imzokitug

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Nashville, Tennessee, United States and 70 other locations

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

and osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ...

Active, not recruiting
Non-Small Cell Lung Cancer (NSCLC)
Drug: Osimertinib
Drug: HER3-DXd

Phase 1

Daiichi Sankyo
Daiichi Sankyo

Nashville, Tennessee, United States and 30 other locations

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS ...

Enrolling
Metastatic Non-Small Cell Lung Cancer
Advanced Lung Carcinoma
Drug: Pembrolizumab
Drug: BBO-10203

Phase 1

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Nashville, Tennessee, United States and 34 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems